Valneva-Pfizer Lyme Shot Stumbles Yet Keeps Regulatory Path Alive

The Phase 3 VALOR trial results showed that fewer Lyme disease cases were accrued than anticipated, and the primary endpoint was not met in the first analysis.Secondary Analysis For Valneva DrugHowever, the second analysis indicated clinically meaningful efficacy, with Pfizer expressing confidence in the vaccine’s potential and planning submissions to regulatory authorities.In the pre-specified analyses:Efficacy of 73.2% from 28 days post-dose 4 (season 2) in reducing the rate of confirmed Lyme disease case ...